Grant of Options and PDMR Dealing

RNS Number : 2466S

Oncimmune Holdings PLC

13 July 2022

 

13 July 2022

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Grant of Options and PDMR Dealing

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, today announces that options to subscribe for ordinary shares of £0.01 each in the Company ("Ordinary Shares") have been granted to Alistair Macdonald following his appointment as the Company's Non-executive Chair on 8 July 2022.

Alistair Macdonald has been granted 127,389 options at an exercise price of £0.785 per Ordinary Share and 492,252 options (the "Scheme Options") at an exercise price of £0.01 per Ordinary Share pursuant to the incentivisation scheme established for members of senior management in September 2020 (the "Scheme"). The Scheme Options will vest based on the performance of the Company's share price over the course of the three years from the establishment of the Scheme, between £2.00 and £3.50 ("Target Share Price") (as set out below), which must be achieved for 20 consecutive business days or on certain trigger event.  This vesting mechanism is directly aligned with the delivery of shareholder value. Once vested, Options (or resulting shares) must be held for a further two years, subject to certain exceptions and acceleration events. The Target Share Prices and associated vesting levels for Alistair Macdonald's Scheme Options are as follows:

Target Share Price
£2.00	£2.50	£2.75	£3.00	£3.50
Percentage of Award Vesting
25%	50%	62.5%	75%	100%
Total Number of Options Vesting
123,063	246,126	307,658	369,189	492,252

The Scheme Options granted to Alistair Macdonald replace the unvested options granted to former Chair Meinhard Schmidt in September 2020, which have now lapsed following Meinhard's retirement from the Board.

This announcement, including the notification below, is made in accordance with the requirements of the UK Market Abuse Regulation and serves as notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMR") and persons closely associated with them.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Alistair Macdonald
2	Reason for the notification
a)	Position/status	Non-executive Chair
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Oncimmune Holdings plc
b)	LEI	213800HCYIWT6YPI1I02
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of £0.01 each
	Identification code	ISIN: GB00BYQ94H38
b)	Nature of the transaction	1) Grant of options 2) Grant of Scheme Options
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			1) £0.785	127,389
			2) £0.01	492,252
d)	Aggregated information	N/A - single transactions
	- Aggregated volume
	- Price
e)	Date of the transaction	12 July 2022
f)	Place of the transaction	Outside a trading venue

For further information:

Oncimmune Holdings plc

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

[e-mail]

Singer Capital Markets (Nominated Adviser and Joint Broker)

Aubrey Powell, Harry Gooden, George Tzimas, James Fischer

[phone]

WG Partners (Joint Broker)

David Wilson, Nigel Barnes, Erland Sternby

[phone]

Media enquiries:

John Goold

[e-mail]

About Oncimmune

ImmunoINSIGHTS Service Business

Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. The ImmunoINSIGHTS service business leverages Oncimmune's technology platform and methodologies across multiple diseases, to offer life-science organizations actionable insights for therapies across the development and product lifecycle. Our core immune-profiling technology is underpinned by our library of over eight thousand immunogenic proteins, one of the largest of its kind. This helps identify trial participants and patients into clinically relevant subgroups, enabling development of targeted and more effective treatments.

Oncimmune's ImmunoINSIGHTS service business is based at the Company's discovery research centre in Dortmund, Germany. The business platform enables life science organizations to optimize drug development and delivery, leading to more effectively targeted and safer treatments for patients.

The ImmunoINSIGHTS development team is based in the US and Europe and Oncimmune is seeking to replicate the Dortmund facility in the US in the medium term.

EarlyCDT Product Business

Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung, targets a vast market estimated to grow to £3.8bn by 2024. With over 200,000 tests already performed for patients worldwide and its use being supported by peer reviewed data in over 12,000 patients, we are poised to become an integral component of future lung cancer detection programs, globally.

Oncimmune's diagnostic products business is located at its laboratory facility in Nottingham, UK.

For more information, visit www.oncimmune.com

What is SeroTag^TM?

Oncimmune's proprietary biomarker discovery engine, which is leveraged in our ImmunoINSIGHTS services to discover and validate novel biomarkers can help stratify patients in multiple cancer indications and with different autoimmune diseases.

This high-throughput, multiplex technology is based on one of the largest, in-house protein libraries, as well as a unique, ever-growing repository of disease data for indications including, but not limited to, autoimmune diseases and cancer. As a result, SeroTag is helping to address and monitor a number of challenges currently hindering the successful development and broader application of both cancer immunotherapies and treatments for autoimmune diseases.

The platform is being applied to discover and validate biomarkers and develop precision diagnostic tools from minimally invasive liquid biopsies. SeroTag analyses autoantibodies-some of the most stable analytes-and is used most frequently for the identification of IgG isoforms, in addition to IgM and IgA, from just a few drops of serum.

The SeroTag platform acts as the primary discovery engine that feeds into the creation of Oncimmune's NavigAID^TM disease-specific stratification panels. These precision medicine tools which are enabling patient and disease stratification and support therapeutic development.

 

END

 

 

DSHBKBBBFBKDDOD